Cover Image

HARDBACK
$52.95



View/Hide Left Panel

 

COST INCURRED BY DISEASE

Table A6–1 summarizes the health care costs incurred by EBV infections. For the purposes of the calculations in this report, it was assumed that patients with uncomplicated mononucleosis incur costs associated with a physician visit, a diagnostic, and medications. Patients with complicated mononucleosis incur slightly more costs due to more physician visits (to a specialist) and more expensive diagnostics.

VACCINE DEVELOPMENT

The committee assumed that the development of an EBV vaccine is feasible and that licensure can occur within the time frame of its charge, but is not imminent. The estimates for the model are that it will take 15 years until licensure and that $390 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

The committee’s model assumes that immunization with this vaccine will occur during puberty. As described in the body of the report, for these purposes, that is set at 12 years of age. Both males and females would receive the immunization. It is estimated that only 50% of the target population will accept the immunization.

Vaccine Schedule, Efficacy, and Costs

The committee estimated that this would be a relatively low-cost vaccine, costing $50 per dose. Vaccine administration would cost an additional $10. The committee has accepted default assumptions for this vaccine that it will require a series of 3 doses and that effectiveness will be 75%. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for EBV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement